Claficapavir

• CAT Number: I045115
• CAS Number: 2055732-24-4
• Molecular Formula: C17H12ClNO4S2
• Molecular Weight: 393.86
• Purity: ≥95%
• Synonyms: 3-[(5Z)-5-[[5-(4-chlorophenyl)furan-2-yl]methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]propanoic acid
• InChI: InChI=1S/C17H12ClNO4S2/c18-11-3-1-10(2-4-11)13-6-5-12(23-13)9-14-16(22)19(17(24)25-14)8-7-15(20)21/h1-6,9H,7-8H2,(H,20,21)/b14-9-
• InChIKey: YZLFZFALAZYTCI-ZROIWOOFSA-N
• SMILES: C1=CC(=CC=C1C2=CC=C(O2)/C=C\3/C(=O)N(C(=S)S3)CCC(=O)O)Cl

Claficapavir（Cat No.:I045115）is an investigational capsid inhibitor developed for the treatment of chronic hepatitis B virus (HBV) infection. It targets the HBV core protein, disrupting capsid assembly and inhibiting multiple stages of the viral life cycle, including genome replication and cccDNA formation. Designed for potent antiviral activity, Claficapavir may be used in combination with other agents to achieve a functional cure. Its novel mechanism offers advantages over nucleos(t)ide analogs by addressing persistent viral reservoirs. Supplied for research into HBV virology, capsid-targeted therapies, and curative antiviral strategies.